肠易激综合征患者愿意为缓解症状承担显著用药风险
该调查纳入215例符合Rome IV标准的肠易激综合征(IBS)患者,评估其用药风险意愿与支付意愿。腹泻型IBS患者为获得99%治愈机会平均可接受10.2%±15.7%的猝死风险;疼痛灾难化评分与用药风险意愿无关;患者每月愿支付金额随年收入不同而异。
要点
- 腹泻型IBS患者为99%治愈机会可接受平均10.2%的猝死风险。
- 疼痛灾难化评分未增加患者承担用药风险的可能性。
- 患者对缓解疼痛的月支付意愿随年收入水平不同。
核心结论
- 腹泻型IBS患者愿意为改善症状承担极大风险,而疼痛灾难化患者不然。
- 临床医生了解患者用药风险意愿有助于指导复杂治疗选择。
研究设计与样本
- 邮寄问卷调查符合Rome IV标准的IBS患者,共215例 respondents,81.8%为女性,平均年龄57岁。
- 采用标准博弈法评估用药风险意愿,并通过支付意愿问题量化假设药物的最高支出。
主要发现
- 受访者IBS症状平均持续17.7年。
- 以严重腹泻为主要症状的腹泻型IBS患者,为99%治愈机会平均接受10.2%±15.7%的猝死风险。
- 疼痛灾难化量表评分与承担用药风险的可能性增加无关。
- 年收入<75,000美元者平均愿每月支付73美元,年收入>75,000美元者平均愿每月支付197美元以缓解疼痛。
临床怎么用
- 临床沟通中可考虑评估IBS患者对用药风险的接受度,以个体化讨论治疗选项。
- 对腹泻型IBS患者,医生应了解其可能愿意承担较高风险,需充分告知风险与获益。
- 对疼痛灾难化评分高的患者,不应假定其更愿意承担用药风险。
局限性
- 原文未明确报告调查应答率及无应答偏倚。
- 样本以女性为主且平均年龄57岁,可能限制结果外推。
- 支付意愿基于假设性药物情景,与实际支出可能存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is a common chronic functional bowel disorder for which patients take significant risks to ameliorate symptoms. Unfortunately, there is no cure for IBS. We assessed the willingness of patients with IBS to take medication risks and the costs they would pay to improve symptoms. METHODS: We mailed a survey on medication risk to patients with IBS who met the Rome IV criteria. The survey collected data on patient demographics, symptoms, medication use, prior medication-averse events, and pain catastrophization. A standard gamble evaluated respondents' willingness to take medication risks, and a willingness-to-pay set of questions quantified maximal spending on a hypothetical medication to treat IBS. RESULTS: Among respondents (n = 215; 81.8% female; mean age, 57 y) the average duration of IBS symptoms was 17.7 years. Patients whose predominant symptom was severe diarrhea (diarrhea-predominant IBS) reported accepting a mean 10.2% ± 15.7% risk of sudden death for a 99% chance of cure. Pain catastrophizing scale scores were not associated with an increased likelihood of taking medication risks. Patients with IBS would be willing to pay an average amount of $73 per month (if annual income was <$75,000) and $197 per month (if annual income was >$75,000) for a medication that would resolve their pain. CONCLUSIONS: In a survey of 215 patients with IBS, we found that patients with diarrhea-predominant IBS are willing to take extraordinary risks to improve their symptoms, whereas patients with IBS and pain catastrophization are not. Clinician understanding of patients' willingness to take medication risks might help them guide their patients through complex therapeutic options.
引用
- Shah SL, Janisch NH, Crowell M, et al. Patients With Irritable Bowel Syndrome Are Willing to Take Substantial Medication Risks for Symptom Relief. Clin Gastroenterol Hepatol. 2020. PMID: 32289536. doi:10.1016/j.cgh.2020.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。